Understand · Treat · Recover

Molecular Biomarkers and Precision Oncology

Biomarkers are measurable tumour features that can help select treatment. The right test depends on the clinical setting.

For patients, families and caregivers worldwide. Approvals, access and care pathways vary by country. Evidence checked 21 October 2026.

This information is provided for general educational purposes and does not replace individualized medical advice. Diagnosis and treatment decisions should be made with a qualified healthcare team.

Chapter 7 of 20

Established tests in advanced adenocarcinoma

MarkerHow it is assessedPotential treatment relevance
HER2Gastric-specific IHC scoring; IHC 2+ generally needs confirmatory ISHTrastuzumab-based treatment and later HER2-directed therapy in eligible disease.
PD-L1 CPSIHC; combines stained tumour and selected immune cells relative to viable tumour cellsHelps determine eligibility and likely benefit from particular checkpoint-inhibitor combinations.
MSI / MMRMMR protein IHC or validated MSI testingIdentifies repair-deficient biology with important immunotherapy implications.
CLDN18.2Validated IHC assay and treatment-specific thresholdZolbetuximab plus chemotherapy in eligible HER2-negative advanced disease.

Understanding the numbers

For gastric HER2 testing, IHC 3+ is positive; equivocal IHC 2+ needs gene-amplification testing such as ISH. Gastric scoring differs from breast scoring. CPS is a score, not the percentage chance that immunotherapy will work. Cut-offs are drug-, setting- and country-specific. The zolbetuximab studies used moderate-to-strong membranous CLDN18 staining in at least 75% of tumour cells with the validated assay. A report saying simply “positive” may need clarification.

NGS and uncommon opportunities

Next-generation sequencing surveys multiple DNA or RNA alterations. It can identify rare changes such as NTRK fusions and, in appropriate jurisdictions, other tumour-agnostic treatment opportunities. NTRK overexpression is not the same as a confirmed fusion. A genetic report may also identify variants without an effective matched treatment. NGS does not automatically replace HER2, PD-L1 or CLDN18.2 protein testing.

When repeat testing helps

HER2 expression can be patchy or lost after HER2-directed treatment. A new biopsy after progression may help confirm eligibility for trastuzumab deruxtecan. Inadequate tissue, an unexpected result or a different metastatic site can justify pathology review or repeat testing. Blood-based profiling can sometimes supplement tissue but may miss alterations and does not replace every tissue assay.

Established versus emerging

FGFR2b-directed approaches, new CLDN18.2 treatments, cell therapies and additional antibody–drug conjugates are active research areas; any proposed use needs a current local approval or trial-specific eligibility check. Circulating tumour DNA after curative treatment is promising, but should not automatically dictate starting or stopping treatment outside an evidence-based pathway. Ask which result changes the decision today, how long testing takes and whether a germline referral is needed.

A current-label example

The US pembrolizumab label checked in 2026 specifies PD-L1 CPS ≥1 for first-line HER2-negative gastric/GEJ treatment with chemotherapy, and for its trastuzumab-containing HER2-positive combination. Current US nivolumab gastric/GEJ labeling also requires PD-L1 expression ≥1. These examples are country-specific; other jurisdictions and guideline preferences can use different thresholds.

Key takeaways

Ask for the actual assay, score and treatment implication—not only a positive or negative label.

Frequently asked questions

Is PD-L1-negative the same as MSI-stable?

No. They measure different biology.

Does HER2 positivity mean inherited cancer?

Usually not. A tumour HER2 result is not a hereditary diagnosis.

Can more than one marker be positive?

Yes. The team must choose an evidence-supported combination; adding every available drug is not established care.

Does a target guarantee response?

No. It identifies a potential treatment opportunity, not a promise.

Does everyone need broad NGS immediately?

Prioritise established tests that affect the current plan, then consider broader testing where useful.

Should MSI-high prompt family testing?

It may prompt assessment for Lynch syndrome, but many MSI-high gastric cancers are not inherited.

References and further reading